comparemela.com

Latest Breaking News On - Bart filius - Page 6 : comparemela.com

Galapagos NV: Galapagos demonstrates regulatory and commercial progress in Q1 2022

First three months 2022 financial results: Jyseleca net sales reached €14.4 millionGroup revenues +20% to €136.3 millionOperating loss -58% to €21.1 millionCash

Region flamandeUnited statesUnited kingdomCzech republicGreat britainPaul stoffelsVan gijselBart filiusSandra cauwenberghsMarieke vermeerschToledo sikiDan bakerBelgian companiesRegulatory agency in great britainMinistry of healthEuropean commission

Galapagos demonstrates regulatory and commercial progress in Q1 2022

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Region flamandeUnited kingdomCzech republicGreat britainToledo sikiPaul stoffelsiDan bakerVan gijselPaul stoffelsBart filiusMarieke vermeerschSandra cauwenberghsBelgian companiesRegulatory agency in great britainMinistry of healthEuropean commission

Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos demonstrates regulatory and commercial progress in Q1 2022

Investegate announcements from Galapagos NV, Galapagos demonstrates regulatory and commercial progress in Q1 2022

Region flamandeUnited statesUnited kingdomCzech republicGreat britainPaul stoffelsVan gijselBart filiusSandra cauwenberghsMarieke vermeerschToledo sikiDan bakerBelgian companiesRegulatory agency in great britainMinistry of healthEuropean commission

Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos 2021 results set stage for future growth

Investegate announcements from Galapagos NV, Galapagos 2021 results set stage for future growth

Region flamandeUnited statesUnited kingdomGreat britainToledo sikiEli lillyVan gijselJaki mahsPaul stoffelsBart filiusMarieke vermeerschSandra cauwenberghsPharmacovigilance risk assessment committeeEuropean commissionData monitoring committeeGilead sciences inc

Galapagos NV: Galapagos 2021 results set stage for future growth

Key 2021 and post period events: Appointment of Dr. Paul Stoffels1 as new CEO, effective 1 April 2022, following planned retirement of CEO and co-founder Onno van de StolpeJyseleca sales booked by

Region flamandeUnited kingdomGreat britainToledo sikiEli lillyVan gijselJaki mahsPaul stoffelsBart filiusMarieke vermeerschSandra cauwenberghsPharmacovigilance risk assessment committeeEuropean commissionData monitoring committeeGilead sciences incRegulatory agency

vimarsana © 2020. All Rights Reserved.